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POST 2 Study: Patients with Vasovagal Syncope 
Improved Modestly with Fludrocortisone 0.2 mg daily 
with Insignificant 31% Reduction in the Hazard of 
Fainting in the Intent-to-Treat Analysis 
Among 210 patients (71% female, median age 30 years) 
with recurrent vasovagal syncope randomized to fludrocor-
tisone or placebo at highest tolerated doses from 0.05 mg to 
0.2 mg daily, there was a marginally nonsignificant reduction 
in syncope in the fludrocortisone group (hazard ratio - HR: 
0.69; p=0.069). In a multivariable model, fludrocortisone 
significantly reduced the likelihood of syncope (HR: 0.63; 
p=0.024). When the analysis was restricted to outcomes after 
2 weeks of dose stabilization, there was a significant benefit 
due to fludrocortisone (HR: 0.51; p=0.019) (Sheldon R et al, 
J Am Coll Cardiol 2016;68:1-9). 
Patients With Variant Angina Presenting With Aborted 
Sudden Arrhythmic Death (SCD) Face a Worse 
Prognosis Than Those Without SCD, While Therapy 
With Vasodilator Drugs is not Sufficiently Protective / 
Additional ICD Implantation Might be Necessary as a 
Secondary Prevention Treatment 
Among 188 patients with variant angina with atheroscle-
rosis (ASCD) and 1,844 patients with variant angina without 
ASCD (predictors of ASCD: age, hypertension, hyperlipidemia, 
family history of sudden cardiac death, multivessel spasm, 
and left anterior descending artery spasm), over a median of 
7.5 years, the incidence of cardiac death was higher in ASCD 
patients (24.1 vs 2.7 per 1,000 patient-years; hazard ratio - HR: 
7.26; p <0.001). Death from any cause also occurred more 
frequently in ASCD patients (27.5 vs 9.6 per 1,000 patient-
years; HR: 3; p <0.001). The incidence rate of recurrent 
ventricular tachyarrhythmia in ASCD patients was 32.4 per 
1,000 patient-years, and the composite of cardiac death and 
ventricular tachyarrhythmia was 44.9 per 1,000 patient-years. 
A total of 24 ASCD patients received ICDs (Ahn JM et al, J 
Am Coll Cardiol 2016;68:137-145).
High-Output Heart Failure (HF): The Most Frequent 
Causes Have Changed Over Time, and Today Include 
Obesity, Liver Disease, and Arteriovenous Fistulas, 
Although Pulmonary and Myeloproliferative Diseases 
are Additional, Underappreciated Causes / Outcomes 
Differ Little From Those in Patients With Low-Output 
HF Due to Systolic Dysfunction
The most common etiologies of high-output HF (n=120) 
were obesity (31%), liver disease (23%), arteriovenous shunts 
(23%), lung disease (16%), and myeloproliferative disorders 
(8%). Compared with controls (n=24), subjects with high-
output HF displayed eccentric left ventricular remodeling, 
greater natriuretic peptide activation, higher filling pres-
sures, pulmonary hypertension, and increased cardiac output, 
despite similar ejection fraction. Mortality was increased in 
high-output HF as compared with controls (hazard ratio: 3.4). 
Hemodynamics and outcomes were poorest amongst patients 
with the lowest systemic vascular resistance (Anand IS et al, 
N Engl J Med 2016;68:483-486). 
Early Strokes in Patients with TAVI: Predictors 
Comprise Female Sex, Chronic Kidney Disease, New-
Onset AF, and Early Phase of Implementation at a 
Clinical Site / Valve Type (Balloon-Expandable Vs. Self-
Expandable) and Vascular Access Route (Transfemoral 
vs Nontransfemoral) Are Not 
Analysis of 64 studies comprising 72,318 patients (2,385 
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patients with a stroke within 30 days post-TAVI) showed an 
incidence of strokes of 1-11% (median 4%). The RRs indicated 
lower risk for men (RR: 0.82; p=0.02) and higher risk for 
patients with chronic kidney disease (RR: 1.29; p=0.03) and 
with new-onset AF post-TAVI (RR: 1.85; p=0.005), and for 
procedures performed within the first half of center experi-
ence (RR: 1.55; p=0.003). The use of balloon post-dilation 
tended to be associated with a higher risk (RR: 1.43; p=0.07). 
Valve type (balloon-expandable vs. self-expandable, p=0.26) 
and approach (transfemoral vs. nontransfemoral, p=0.81) 
were not predictors (Auffret VM et al, J Am Coll Cardiol 
2016;68:673-684).
RE-LY Trial: Presence of any Valvular Heart Disease 
(VHD) did not Influence the Comparison of Dabigatran 
with Warfarin
In a post hoc analysis of the RE-LY trial, there were 3950 
patients with any VHD: 3101 with mitral regurgitation, 1179 
tricuspid regurgitation, 817 aortic regurgitation, 471 aortic 
stenosis, and 193 with mild mitral stenosis. At baseline, pa-
tients with any VHD had more heart failure, coronary disease, 
renal impairment, and persistent AF. Patients with any VHD 
had higher rates of major bleeds (hazard ratio - HR, 1.32) 
but similar stroke or systemic embolism event rates (HR, 
1.09). For patients receiving dabigatran 110 mg, major bleed 
rates were lower than for patients taking warfarin (HR, 0.73 
with VHD; HR, 0.84 without VHD), and major bleed rates 
for dabigatran 150 mg were similar to those for warfarin in 
patients with VHD (HR, 0.82) or without VHD (HR, 0.98). 
For dabigatran 150 mg, stroke/systemic embolic event rates 
were lower compared with warfarin in those with VHD (HR, 
0.59) and those without VHD (HR, 0.67), and stroke/ systemic 
embolic event rates were similar for warfarin and dabigatran 
110 mg regardless of the presence of VHD. Intracranial bleeds 
and death rates for dabigatran 150 and 110 mg were lower 
compared with warfarin independently of the presence of 
VHD (Ezekowitz MD et al, Circulation 2016;134:589-598). 
A History of AF in Patients Undergoing PCI is 
Associated With an Increased Risk of In-Hospital 
Adverse Outcomes, Including Bleeding, Post-Procedural 
Heart Failure, Cardiogenic Shock, and Mortality
Among 113,283 PCI cases, history of AF was present in 
13,912 patients (12%), who were older and more likely to 
have comorbid congestive heart failure, cardiomyo-pathy, 
cerebrovascular disease, and chronic lung disease. Patients 
with a history of AF were more likely to have in-hospital 
complications, including in-hospital mortality (3% vs 1%). 
In propensity-matched analysis, patients with a history of AF 
were more likely to be treated with a bare-metal stent (27% 
vs 18%). In the propensity-matched model, AF remained in-
dependently associated with an increased risk of developing 
post-procedural bleeding (odds ratio - OR: 1.32), heart failure 
(OR: 1.33), cardiogenic shock (OR: 1.26), and in-hospital 
mortality (OR: 1.41) (Sutton NRD et al, J Am Coll Cardiol 
2016;68:895-904).
OMEGA-REMODEL Trial: A Beneficial Effect for 
High-Dose Omega-3 Fatty Acid Treatment on Adverse 
LV Remodeling After Acute MI with Attenuation 
of Fibrosis Within Noninfarcted Myocardium and 
Lower Levels of Systemic Biomarkers of Myocardial 
Inflammation and Cardiac Fibrosis
Among patients presenting with an acute MI, randomly 
assigned to 6 months of high-dose omega-3 fatty acids (n=180) 
or placebo (n=178), active treatment patients experienced a 
significant reduction of LV systolic volume index (-5.8%, 
P=0.017), and noninfarct myocardial fibrosis (-5.6%, P=0.026). 
Per-protocol analysis revealed that those patients who achieved 
the highest quartile increase in red blood cell omega-3 index 
experienced a 13% reduction in LV systolic volume index in 
comparison with the lowest quartile. In addition, patients in 
the omega-3 fatty acid arm underwent significant reductions 
in serum biomarkers of systemic and vascular inflammation 
and myocardial fibrosis with no adverse events (Heydari B 
et al, Circulation 2016;134:378-391).
Associations Between Food Fortification With Folic 
Acid and Reductions in the Birth Prevalence of Specific 
Congenital Heart Disease (CHD) Subtypes
Among 5,901,701 live births and stillbirths, the overall 
birth prevalence rate of CHDs was 12.3 per 1000 total births. 
Rates of most CHD subtypes decreased between 1990 and 2011 
except for atrial septal defects, which increased significantly. 
Folic acid food fortification was associated with lower rates 
of conotruncal defects (rate ratio - RR, 0.73), coarctation of 
the aorta (RR, 0.77), ventricular septal defects (RR, 0.85), and 
atrial septal defects (RR, 0.82) but not severe nonconotrun-
cal heart defects (RR, 0.81) and other heart or circulatory 
system abnormalities (RR, 0.98) (Liu S et al, Circulation 
2016;134:647-655).
Higher Free T4 (FT4) Levels are Associated with an 
Increased Risk of SCD, even in Euthyroid Participants
Among 10,318 participants from the Rotterdam Study 
≥45 years with thyroid-stimulating hormone or free thyroxine 
(FT4) measurements there were 261 incident sudden cardiac 
deaths (SCDs) (median follow-up, 9.1 years). Higher levels 
of FT4 were associated with an increased SCD risk, even in 
the normal range of thyroid function (hazard ratio, 2.28 per 
1 ng/dL FT4). Stratification by age or gender and sensitivity 
analyses did not change the risk estimates substantially. The 
absolute 10-year risk of SCD increased in euthyroid partici-
pants from 1% to 4% with increasing FT4 levels (Chaker L 
et al, Circulation 2016;134:713-722).
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CHAMPION PHOENIX trial: Cangrelor Compared with 
Clopidogrel Significantly Reduces MI
A total of 462 (4.2%) among 11,145 patients having per-
cutaneous coronary intervention (PCI) had an MI. Treatment 
with cangrelor reduced the incidence of MI at 48 hours (3.8% vs 
4.7%; odds ratio - OR, 0.80; P=0.02). Similar effects were seen 
in the evaluation of the effects of cangrelor on MIs of different 
definitions. MIs defined by any of definitions were associated 
with increased risk of death at 30 days. Treatment with cangrelor 
reduced the composite end point of death, MI, ischemia-driven 
revascularization, or definite stent thrombosis (1.4% vs 2.1%; 
OR, 0.69) (Cavender MA et al, Circulation 2016;134:723-733). 
Long QT 3: β-Blocker Therapy Reduces the Risk of 
Life-threatening Cardiac Events in Females / Efficacy in 
Males could not be Determined Conclusively Because of 
the Low Number of Events
Among 391 LQT3 patients known to be event free dur-
ing the first year of life, 118 (41 males, 77 females) (30%) 
experienced at least 1 cardiac event (CE) (syncope, aborted 
cardiac arrest, or long-QT syndrome–related sudden death), 
and 24 (20%) suffered from LQT3-related aborted cardiac 
arrest/sudden death. The risk of a first CE was directly re-
lated to the degree of QTc prolongation. Time-dependent 
β-blocker therapy was associated with an 83% reduction in 
CEs in females (P=0.015) but not in males (who had many 
fewer events), with a significant sex × β-blocker interaction 
(P=0.04). Each 10-ms increase in QTc duration up to 500 ms 
was associated with a 19% increase in CEs. Prior syncope 
doubled the risk for life-threatening events (P <0.02) (Wilde 
AAM et al, Circulation 2016;134:872-882).
VANISH: In Patients with Ischemic Cardiomyopathy 
and an ICD and Ventricular Tachycardia (VT) Despite 
Drug Therapy, Ablation Decreased Death, VT Storm, or 
Appropriate ICD Shocks
Of 259 patients, 132 were assigned to ablation and 127 to 
escalated drug-therapy. During a mean of 27.9±17.1 months, 
the primary outcome (death, VT storm or appropriate ICD 
shocks) occurred in 59.1% of patients in the ablation group 
and 68.5% of the escalated-therapy group (hazard ratio in 
the ablation group, 0.72; P=0.04). There was no significant 
between-group difference in mortality. There were two cardiac 
perforations and three cases of major bleeding in the ablation 
group and two deaths from pulmonary toxic effects and one 
from hepatic dysfunction in the escalated-therapy group (Sapp 
JL et al, N Engl J Med 2016; 375:111-121).
LEADER Trial: Lower Rate of Cardiovascular Death, 
MI, or Stroke in Diabetic Patients With Liraglutide 
Than With Placebo
Among 9340 diabetic patients randomized to liraglutide or 
placebo, at a median follow-up of 3.8 years, the primary outcome 
(cardiovascular death, MI or stroke) occurred in significantly 
fewer patients in the liraglutide group (608 of 4668 patients 
or 13%) than in the placebo group (694 of 4672 or 14.9%) 
(hazard ratio-HR, 0.87; P<0.001 for noninferiority; P=0.01 for 
superiority). Fewer patients died from cardiovascular causes in 
the liraglutide group (219 patients or 4.7%) than in the placebo 
group (278 or 6%) (HR, 0.78; P=0.007). The rate of death from 
any cause was lower in the liraglutide group (381 patients or 
8.2%) than in the placebo group (447 or 9.6%) (HR, 0.85; 
P=0.02). The rates of MI, stroke, and hospitalization for heart 
failure were nonsignificantly lower in the liraglutide group. The 
most common adverse events leading to the discontinuation 
of liraglutide were gastrointestinal events. The incidence of 
pancreatitis was nonsignificantly lower in the liraglutide group 
(Marso SP et al, N Engl J Med 2016; 375:311-322).
DANISH Trial: Prophylactic ICD Implantation in Patients 
With Nonischemic Cardiomyopathy Was Not Associated 
With a Significantly Lower Long-Term Mortality
After a median of 67.6 months, among 556 non-ischemic 
cardiomyopathy patients with symptomatic systolic heart 
failure (ejection fraction, ≤35%) assigned to receive an ICD, 
and 560 patients assigned to receive usual clinical care (control 
group) (58% receiving CRT in both groups), total mortality 
occurred in 120 patients (21.6%) in the ICD group and in 131 
patients (23.4%) in the control group (hazard ratio-HR, 0.87; 
P=0.28). Sudden death occurred in 24 patients (4.3%) in the 
ICD group and in 46 patients (8.2%) in the control group (HR, 
0.50; P=0.005). Device infection occurred in 27 patients (4.9%) 
in the ICD group & in 20 patients (3.6%) in the control group 
(P=NS) (Køber L et al, N Engl J Med 2016;375:1221-1230). 
NORSTENT Trial: In Patients Undergoing PCI, 
There Were no Significant Differences in Death and 
MI Between those Receiving Drug-Eluting Stents 
(DES) or Bare-Metal Stents (BMS) / Rates of Repeat 
Revascularization Were Lower in the DES Group
At 6 years, among 9013 patients with stable or unstable 
coronary artery disease randomly assigned to undergo PCI with 
the implantation of either contemporary DES (everolimus- or 
zotarolimus-eluting stents) or BMS, the rates of the primary 
outcome (death and MI) were 16.6% in the group receiving 
DES and 17.1% in the BMS group (hazard ratio-HR, 0.98; 
P=0.66). The 6-year rates of any repeat revascularization were 
16.5% in the group receiving DES and 19.8% in the BMS group 
(HR, 0.76; P <0.001); the rates of definite stent thrombosis 
were 0.8% and 1.2%, respectively (P=0.0498). Quality-of-life 
measures did not differ significantly between the two groups 
(Bønaa KH et al, N Engl J Med 2016; 375:1242-1252).
ANNEXA-4: Initial Bolus Followed by 2-Hour Infusion 
of Andexanet Substantially Reduced Anti–Factor 
Xa Activity in Patients With Acute Major Bleeding 
Associated With Factor Xa Inhibitors, With Effective 
Hemostasis Occurring in 79% 
All 67 patients (mean age 77 years) with acute major 
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(gastrointestinal or intracranial) bleeding who received a bolus 
of andexanet, a factor Xa inhibitor, at a mean of 4.8±1.8 h, 
followed by a 2-h infusion of the drug, were evaluated within 
18 h after the administration of a factor Xa inhibitor. After 
the bolus administration, the median anti–factor Xa activity 
decreased by 89% among patients receiving rivaroxaban and 
by 93% among patients receiving apixaban. These levels 
remained similar during the 2-h infusion. At 4 h after the end 
of the infusion, there was a relative decrease from baseline of 
39% in the measure of anti–factor Xa activity among patients 
receiving rivaroxaban and of 30% among those receiving apixa-
ban. At 12 h after the andexanet infusion, clinical hemostasis 
was adjudicated as excellent or good in 37 of 47 patients in 
the efficacy analysis (79%). Thrombotic events occurred in 12 
of 67 patients (18%) during the 30-day follow-up (Connolly 
SJ et al, N Engl J Med 2016; 375:1131-1141). 
SAVE Trial: CPAP did not Prevent Cardiovascular 
Events in Obstructive Sleep Apnea (OSA)
After a mean follow-up of 3.7 years, among 2717 patients 
(45-75 years of age) with OSA randomly assigned to CPAP 
treatment plus usual care (CPAP group) or usual care alone 
(usual-care group), the primary composite end point (death 
from cardiovascular causes, MI, stroke, or hospitalization 
for unstable angina, heart failure, or TIA) occurred in 229 
participants in the CPAP group (17%) and in 207 participants 
in the usual-care group (15.4%) (hazard ratio, 1.10; P=0.34). 
CPAP significantly reduced snoring and daytime sleepiness 
and improved health-related quality of life and mood (McEvoy 
RD et al; N Engl J Med 2016; 375:919-931). 
RELY: Marked Unexplained Inter-Regional Variations  
in Stroke and Mortality Occurrence Suggest that  
Factors Other Than Clinical Variables Might be 
Important / Prevention of Death from Heart Failure 
Should be a Major Priority in Treating Atrial  
Fibrillation (AF)
According to a prospective registry of 15,400 patients in 
47 countries presenting to the emergency department with AF 
or atrial flutter in 8 geographical regions, 1758 (11%) patients 
died within 1 year. Fewer deaths occurred among patients 
presenting with a primary diagnosis of AF compared with 
patients who had AF as a secondary diagnosis (377 or 6% 
of 6825 patients vs 1381 or 16% of 8536, p <0.0001). Twice 
as many patients had died by 1 year in South America (192 
or 17% of 1132) and Africa (225 or 20% of 1137) compared 
with North America, western Europe, and Australia (366 or 
10% of 3800, p <0.0001). Heart failure was the most common 
cause of death (519 or 30% of 1758); stroke caused 148 (8%) 
deaths. 604 (4%) of 15361 patients had had a stroke by 1 year; 
170 (3%) of 6825 for whom AF was a primary diagnosis and 
434 (5%) of 8536 for whom it was a secondary diagnosis (p 
<0.0001). The highest number of strokes occurred in Africa 
(89 or 8% of 1137), China (143 or 7% of 2023), and southeast 
Asia (88 or 7% of 1331) and the lowest occurred in India (20 
or <1% of 2536). 94 (3%) of 3800 patients in North America, 
western Europe, and Australia had a stroke (Healey JS et al, 
Lancet 2016;388:1161–1169). 
PRIMA Trial: In Patients With Refractory Migraine 
With Aura and PFO, PFO Closure did not Reduce 
Overall Monthly Migraine Days
Among 83 patients completing 1-year follow-up of 107 
migraine patients randomly allocated to treatment with an 
Amplatzer PFO Occluder (N=53) or control with medical 
management with aspirin and clopidogrel (N=54), mean mi-
graine days were not significantly reduced (Mattle HP et al, 
Eur Heart J 2016;37:2029-2036).
Important Review and Other Articles 
 - New 2016 ESC Guidelines for Atrial Fibrillation (Kirch-
hof P et al, Eur Heart J 2016;37:2893-2962), Non-statin 
therapies (ACC Expert Consensus) for LDL-cholesterol 
lowering (Lloyd-Jones DM et al, JACC 2016;68:92-125), 
Spontaneous coronary artery dissection (Saw J et al, J Am 
Coll Cardiol 2016;68:297-312.), High-risk cardiac disease 
in pregnancy (Elkayam U et al, JACC 2016; ;68:396-410 & 
502-516), Cardiac sarcoidosis (Birnie DH et al, J Am Coll 
Cardiol 2016;68:411-421), Left ventricular non-compaction 
(Arbustini E et al, J Am Coll Cardiol 2016;68:949-966), 
Duration of dual antiplatelet therapy in patients with CAD 
(Levine et al, J Am Coll Cardiol 2016;68:1082-1115 & 
Bittl JA et al, J Am Coll Cardiol 2016;68:1116-1139), 
Contrast-induced acute kidney injury (McCullough PA 
et al, J Am Coll Cardiol 2016;68:1465-1473), Pharmaco-
logical therapy for heart failure (Yancy CW et al, J Am 
Coll Cardiol 2016;68:1476-1488), Bioresorbable vascular 
scaffolds (Kereiakes DJ et al, Circulation 2016; 134:168-
182), Management of bleeding with NOACs (Ruff CT 
et al, Circulation 2016;134:248-261), AF ablation (Link 
MS et al, Circulation 2016;134:339-352), Drugs causing 
or exacerbating heart failure (Page RL et al, Circulation 
2016;134:e32-e69), Chest compression only CPR (Ewy 
GA, Circulation 2016;134:695-697), Atrial fibrillation 
(stroke prevention / rate & rhythm control) (Lancet 2016; 
388: 806-840).
Addendum (Just in!): On October 28, 2016, based on the 
accumulated evidence, the U.S. Food and Drug Administration 
approved the Amplatzer PFO Occluder device for prevention 
of recurrent strokes in patients with a cryptogenic stroke and 
a PFO (http://www.fda.gov/NewsEvents/Newsroom/Pres-
sAnnouncements/ucm527096.htm).
